ARCHIVES

Q&A: Data that Killed CYP2D6 Testing Contradict Fundamental Law of Nature

This article is from The Cancer Letter archive.

Vol. 38 No. 20 | May 18, 2012

Download PDF Visit The Full Archive

Related Articles

Choice Of Reconstruction Can Depend On Who Consults

October 29, 2010

Vanderbilt-Ingram Wins NCI SPORE Grant

April 19, 2002

Drug Cleared For GIST And Kidney Cancer, FDA’s First Two-Indication Cancer Approval

January 27, 2006

DCE Advisors Okay Contract Recompetitions For Epidemiology

November 18, 1994

Aventis, MediGene In Pact For Development Of Vaccine.

February 25, 2000

NCI Continues Making Improvements In Contract Management

May 22, 1981